Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripAtara Biotherapeutics is putting the key back in the ignition for Ebvallo (tabelecleucel) as the US Food and Drug Administration has lifted the clinical hold that it placed on the program in January,